Catalan pharmaceutical Almirall sells its respiratory subsidiary to AstraZeneca for €1.56 billion
On Wednesday the Catalan pharmaceutical company Almirall announced that they have sold the rights to their respiratory subsidiary to the British-Swedish company AstraZeneca for the initial value of €653 million ($875 million), to be paid when signing the deal. Then, further payments could reach up to an additional €910 million ($1.22 billion), depending on the AstraZeneca's success in product development, new product launches and sales. This news comes after Almirall announced a €19.1 million net profit in the first two quarters of this year, an 8.5% increase from the same period last year. With this new operation it is expected that "a significant number" of employees from the Catalan company's respiratory subsidiary will be transferred to AstraZeneca.